Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for patients with rare diseases, often addressing conditions with limited or no existing therapeutic options. The company's website is www.jazzpharmaceuticals.com.

Jazz operates a diversified portfolio of marketed products across three primary therapeutic areas: rare sleep disorders, rare epilepsies, and rare oncology. The company's lead products include Xywav, a low-sodium oxybate therapy for narcolepsy and idiopathic hypersomnia that generated $1.657 billion in net product sales in 2025 representing 41 percent of total net product sales; Epidiolex, a cannabidiol-based treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex that generated $1.059 billion in 2025 representing 26 percent of total net product sales; and Rylaze, an asparaginase therapy for acute lymphoblastic leukemia and lymphoblastic lymphoma that generated $402.9 million in 2025 representing 10 percent of total net product sales. Additional marketed products include Zepzelca for small cell lung cancer, Ziihera for HER2-positive biliary tract cancers, and Modeyso for diffuse midline glioma.

The company's strategy emphasizes strong commercial execution, pipeline expansion, and strategic acquisitions to complement its existing portfolio. Jazz maintains an efficient, scalable operating model with integrated global capabilities to reach patients worldwide. The company completed the acquisition of Chimerix in April 2025, adding Modeyso to its rare oncology portfolio. Jazz also divested Sativex to CNX Therapeutics in October 2025.

Jazz's business model focuses on rare diseases characterized by high unmet medical needs and concentrated patient populations, enabling efficient commercialization. The company leverages proprietary intellectual property, regulatory exclusivities including orphan drug designations, and established relationships with healthcare providers and payers. The oxybate franchise, including both Xywav and the legacy Xyrem product, represents a significant portion of revenues, though the company has successfully diversified its revenue base substantially over recent years through product launches and acquisitions.